|
|
| Zeile 1: |
Zeile 1: |
| [[Datei:pptpdtjpg1.png|miniatur|Entstehender Artikel]] | | Pfitzners Hansi stinkt, er ist Nazi und hat oft aufs Maul gekriegt. Deshalb ist er so, wie er ist: Ein Feigling! --[[Benutzer:Ihr könnt mich nicht aufhalten|Ihr könnt mich nicht aufhalten]] ([[Benutzer Diskussion:Ihr könnt mich nicht aufhalten|Diskussion]]) 16:02, 5. Mär. 2013 (CET) |
| {| class="wikitable" |
| |
| | bgcolor="#dfdfdf" | '''Siehe auch'''
| |
| | align="left" width="800" |
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Freie Übersichtsartikel'''
| |
| | align="left" width="800" |<ref name="PMID9182473">Correction of excessive anticoagulation with low-dose oral vitamin K1. Ann Intern Med 126(12):959-62 (1997) PMID 9182473 </ref><ref name="PMID18309033">Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111(10):4871-9 (2008) PMID 18309033 </ref><ref name="PMID18316627">Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 111(9):4471-6 (2008) PMID 18316627 </ref><ref name="PMID15191946">New anticoagulants. Blood 105(2):453-63 (2005) PMID 15191946 </ref><ref name="PMID18574268">Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):257S-298S (2008) PMID 18574268 </ref><ref name="PMID18574265">Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):160S-198S (2008) PMID 18574265 </ref><ref name="PMID9822057">Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114(5 Suppl):445S-469S (1998) PMID 9822057 </ref><ref name="PMID17638939">Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 116(3):305-15 (2007) PMID 17638939 </ref><ref name="PMID18495950">Vitamin K-dependent proteins, warfarin, and vascular calcification. Clin J Am Soc Nephrol 3(5):1504-10 (2008) PMID 18495950 </ref><ref name="PMID17426080">Anticoagulants in heart disease: current status and perspectives. Eur Heart J 28(7):880-913 (2007) PMID 17426080 </ref><ref name="PMID16143706">Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients. Eur Heart J 27(5):519-26 (2006) PMID 16143706 </ref><ref name="PMID19074094">Management of excessive anticoagulant effect due to vitamin K antagonists. Hematology Am Soc Hematol Educ Program ():266-70 (2008) PMID 19074094 </ref><ref name="PMID19074090">New anticoagulants in children. Hematology Am Soc Hematol Educ Program ():245-50 (2008) PMID 19074090 </ref><ref name="PMID15561696">Thrombophilia and new anticoagulant drugs. Hematology Am Soc Hematol Educ Program ():424-38 (2004) PMID 15561696 </ref><ref name="PMID11722992">Anticoagulation therapy. Hematology Am Soc Hematol Educ Program ():339-57 (2001) PMID 11722992 </ref><ref name="PMID18533078">Perioperative management of warfarin therapy: to bridge or not to bridge, that is the question. Mayo Clin Proc 83(6):628-9 (2008) PMID 18533078 </ref><ref name="PMID2686173">Long-term anticoagulation. Indications and management. West J Med 151(4):414-29 (1989) PMID 2686173 </ref><ref name="PMID18294567">"Triple therapy" or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents. J Am Coll Cardiol 51(8):826-7 (2008) PMID 18294567 </ref><ref name="PMID18294566">Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol 51(8):818-25 (2008) PMID 18294566 </ref>
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Wichtige Übersichtsartikel'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Medline Suchterm/ Synonyme'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#00dfdf" | '''Was ist das'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Struktur'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Physiologie'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Knockout'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Transgen'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Mutation'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Polymorphismus'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Genexpression'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Inhibitoren'''
| |
| | align="left" width="800"|
| |
| |-
| |
| | bgcolor="#dfdfdf" | '''Agonisten'''
| |
| | align="left" width="800"|
| |
| |}
| |
| | |
| | |
| == Bibliographie ==
| |
| <references />
| |
| | |
| | |
| | |
| {{LinkWP_Miniartikel}}
| |
Pfitzners Hansi stinkt, er ist Nazi und hat oft aufs Maul gekriegt. Deshalb ist er so, wie er ist: Ein Feigling! --Ihr könnt mich nicht aufhalten (Diskussion) 16:02, 5. Mär. 2013 (CET)
